Barts Cancer Institute & St Bartholomew's Hospital, London
London, United Kingdom
Prof Marco Gerlinger trained in Medicine in Munich, London and Boston and specialised in Medical Oncology in London. He completed his MD at the Institute of Immunology in Munich and undertook post-doctoral research in cancer vaccine development at the University Hospital in Zurich. In 2009, he was awarded an MRC Clinician Scientist Fellowship at the CRUK London Research Institute to investigate predictive biomarkers and evolution in kidney cancers. He was appointed as consultant Medical Oncologist in 2012 at St Bartholomew’s Hospital and in 2013 at the Royal Marsden Hospital where he focused on gastrointestinal cancers. His laboratory is investigating drug resistance evolution, novel ctDNA technologies to track tumour evolution and how the immune system can be harnessed to treat GI cancers. In 2022, he was appointed as Professor of GI Cancer Medicine and Director of GI Cancer Research at the Barts Cancer Institute and St Bartholomew’s Hospital in London. His research is funded by grants from CRUK and the ERC.
Wednesday, June 28, 2023
15:45 – 16:30 CEST